Prevalencia de factores de riesgo para complicaciones derivadas del uso de antiinflamatorios no esteroideos (AINEs) en pacientes con osteoartritis: estudio observacional

Fernando Molina Restrepo; Álvaro Vallejos Narváez; Eleni Paredes Blandon; Gloria Esperanza Castro Osman; Andrés David Díaz Portilla

doi:10.47196/rar.v36i4.1006

Fernando Molina Restrepo Unidad de Osteoporosis, Medellín, Colombia
Álvaro Vallejos Narváez Megalabs Colombia S.A.S., Bogotá, Colombia
Eleni Paredes Blandon Megalabs Colombia S.A.S., Bogotá, Colombia
Gloria Esperanza Castro Osman Megalabs Colombia S.A.S., Bogotá, Colombia
Andrés David Díaz Portilla Compensar EPS, Bogotá, Colombia

DOI: https://doi.org/10.47196/rar.v36i4.1006

Palabras clave: osteoartritis, antiinflamatorios no esteroideos, factores de riesgo, reacciones adversas relacionados con medicamentos, farmacovigilancia

Resumen

Introducción: la osteoartritis (OA) es una patología de alta prevalencia cuyo abordaje farmacológico incluye frecuentemente antiinflamatorios no esteroideos (AINEs), los cuales presentan riesgos significativos. Objetivos: determinar la prevalencia de pacientes con factores de riesgo para complicaciones asociadas al uso de AINEs con diagnóstico de OA. Materiales y métodos: se realizó un estudio observacional, transversal y multicéntrico en 258 pacientes con OA (criterios ACR), con edad ≥38 años. Resultados: se identificó que el 81,7% presentó al menos un factor de riesgo para complicaciones asociadas al uso de AINEs. Los factores de riesgo para complicaciones gastrointestinales fueron los más frecuentes (64,7%), seguidas por las cardiovasculares (60,4%) y renales (8,9%). Conclusiones: se evidenció una elevada prevalencia de factores de riesgo, lo cual subraya la necesidad de un enfoque de prescripción individualizado para minimizar eventos adversos y optimizar la seguridad del tratamiento en esta población vulnerable.

Biografía del autor/a

Fernando Molina Restrepo, Unidad de Osteoporosis, Medellín, Colombia

Unidad de Osteoporosis

Álvaro Vallejos Narváez, Megalabs Colombia S.A.S., Bogotá, Colombia

Megalabs Colombia S.A.S.

Eleni Paredes Blandon, Megalabs Colombia S.A.S., Bogotá, Colombia

Megalabs Colombia S.A.S.

Gloria Esperanza Castro Osman, Megalabs Colombia S.A.S., Bogotá, Colombia

Megalabs Colombia S.A.S.

Andrés David Díaz Portilla, Compensar EPS, Bogotá, Colombia

Compensar EPS

Citas

I. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation. Guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol 2020;72(2):220-33. doi: 10.1002/art.41142.

II. Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA 2021;325(6):568-78. doi: 10.1001/JAMA.2020.22171.

III. Cuervo F, Santos A, Saldarriaga E, Angarita I, Peláez I, Rueda J, et al. Prevalencia de las enfermedades reumáticas en Colombia. Rev Med 2018;40(1):94-5.

IV. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull 2013;105(1):185-99. doi: 10.1093/BMB/LDS038.

V. Jin X, Liang W, Zhang L, Cao S, Yang L, Xie F. Economic and humanistic burden of osteoarthritis: an updated systematic review of large sample studies. Pharmacoeconomics 2023;41(11):1453-67. doi: 10.1007/s40273‑023‑01296‑1.

VI. Towheed T, Marc H, Shea B, George W. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip (Review). Cochrane Database Syst Rev 2006;(1):2-5. doi: 10.1002/14651858.CD000517.

VII. Watson M, Brookes S, Faulkner A, Kirwan J. Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee (Review). Cochrane Database Syst Rev 2006;(1):1-4. doi: 10.1002/14651858.CD000142.

VIII. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther 2013; 15(supp 3):S2. doi: 10.1186/AR4174.

IX. Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthr Cartil 2023;31(4):458-66. doi: 10.1016/J.JOCA.2022.11.005.

X. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 2013;16(5):821-47. doi: 10.18433/J3VW2F.

XI. Baigent C, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9.

XII. Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, Grosser T, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006;4(9):1082-9. doi: 10.1016/j.cgh.2006.04.010.

XIII. Santos ADFO, Alencar ACS, Cruz EES, Duarte FT, Constantino GKG, Duarte JNM, et al. Intoxicação medicamentosa por AINES: uma revisão integrativa. Braz J Heal Rev 2024;7(4):e71066. doi: 10.34119/bjhrv7n4-037.

XIV. Domper Arnal MJ, Hijos-Mallada G, Lanas A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opin Drug Saf 2022;21(3):373-84. doi: 10.1080/14740338.2021.1965988

XV. Salvo F, Fourrier-Réglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011;89(6):855-66. doi: 10.1038/CLPT.2011.45

XVI. Vuković S, Savić Vujović K, Srebro D, Medić B, Ilic-Mostic T. Prevention of renal complications induced by non-steroidal anti-inflammatory drugs. Curr Med Chem 2016;23(19):1953-64. doi: 10.2174/0929867323666160210125920.

XVII. Klomjit N, Ungprasert P. Acute kidney injury associated with non-steroidal anti-inflammatory drugs. Eur J Intern Med 2022;101:21-8. doi: 10.1016/J.EJIM.2022.05.003.

XVIII. Cabassi A, Tedeschi S, Perlini S, Verzicco I, Volpi R, Gonzi G, et al. Non-steroidal anti-inflammatory drug effects on renal and cardiovascular function: from physiology to clinical practice. Eur J Prev Cardiol 2020;27(8):850-67. doi: 10.1177/2047487319848105.

XIX. Lanza FL, Chan FKL, Quigley EMM, Inadomi J, Baroni D, Bernstein D, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104(3):728-38. doi: 10.1038/AJG.2009.115.

XX. Rafaniello C, Ferrajolo C, Sullo MG, Sessa M, Sportiello L, Balzano A, et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacol Res 2016;104:108-14. doi: 10.1016/J.PHRS.2015.12.026.

XXI. Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, et al. Risk of acute myocardial infarction with NSAIDs in real world use. Bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909. doi: 10.1136/BMJ.J1909.

XXII. Weng SE, Hsu WT, Hsiao FY, Lee CM. Non-steroidal anti-inflammatory drugs, renin-angiotensin system blockade or diuretics and risk of acute kidney injury: A case-crossover study. Arch Gerontol Geriatr 2024;123. doi: 10.1016/J.ARCHGER.2024.105394

XXIII. Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int 2015;88(2):396-403. doi: 10.1038/KI.2015.101

XXIV. Hoel RW, Giddings-Connolly RM, Takahashi PY. Polypharmacy management in older patients. Mayo Clin Proc 2021;96(1):242-56. doi: 10.1016/J.MAYOCP.2020.06.012.

XXV. Lee SH, Han CD, Yang IH, Ha CW. Prescription pattern of NSAIDs and the prevalence of NSAID-induced gastrointestinal risk factors of orthopaedic patients in clinical practice in Korea. J Korean Med Sci 2011;26(4):561-7. doi: 10.3346/jkms.2011.26.4.561.

XXVI. Ide J, Shoaibi A, Wagner K, Weinstein R, Boyle KE, Myers A. Patterns of comorbidities and prescribing and dispensing of non-steroidal anti-inflammatory drugs (NSAIDs) among patients with osteoarthritis in the USA: Real-World Study. Drugs and Aging 2024;41(4):357-66. doi: 10.1007/s40266-024-01108-x.

XXVII. Neogi T, Dell’Isola A, Englund M, Turkiewicz A. Frequent use of prescription NSAIDs among people with knee or hip osteoarthritis despite contraindications to or precautions with NSAIDs. Osteoarthr Cartil 2024;32(12):1628-35. doi: 10.1016/j.joca.2024.07.010.

XXVIII. Shinde M, Rodriguez-Watson C, Zhang TC, Carrell DS, Mendelsohn AB, Nam YH, et al. Patient characteristics, pain treatment patterns, and incidence of total joint replacement in a US population with osteoarthritis. BMC Musculoskelet Disord 2022;23(1):1-8. doi: 10.1186/s12891-022-05823-7.

XXIX. Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database. Fundam Clin Pharmacol 2014;28(2):230-5. doi: 10.1111/FCP.12014.

XXX. Mehuys E, De Backer T, De Keyser F, Christiaens T, Van Hees T, Demarche S, et al. Prevalence and management of drug interactions between nonsteroidal anti-inflammatory drugs and antithrombotics in ambulatory care. Br J Clin Pharmacol 2022;88(8):3896-902. doi: 10.1111/BCP.15288.

XXXI. Derry S, Conaghan P, Da Silva J, Wiffen P, Moore R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2016;(4). doi: 10.1002/14651858.cd007400.pub3.

XXXII. Roth SH. Coming to terms with nonsteroidal anti-inflammatory drug gastropathy. Drugs 2012;72(7):873-9. doi: 10.2165/11633740-000000000-00000.

XXXIII. Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA 2018;320(24):2564-79. doi: 10.1001/jama.2018.19319.

XXXIV. Yang W, Sun C, He SQ, Chen JY, Wang Y, Zhuo Q. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis. A systematic review and network meta-analysis. J Gen Intern Med 2021;36(7):2085-93. doi: 10.1007/s11606-021-06755-z

XXXV. Honvo G, Reginster JY, Rabenda V, Geerinck A, Mkinsi O, Charles A, et al. Safety of symptomatic slow-acting drugs for osteoarthritis. Outcomes of a systematic review and meta-analysis. Drugs and Aging 2019;36:65-99. doi: 10.1007/s40266-019-00662-z.

XXXVI. Rovati LC, Girolami F, D’Amato M, Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum 2016;45(4):S34-41. doi: 10.1016/j.semarthrit.2015.10.009.

XXXVII. Ballesteros-Amozurrutia MA. ¿Cómo disminuir el riesgo de toxicidad por AINE? Rev Gastroenterol Mex 2010;75(2):40-2.

XXXVIII. Lewis JD, Kimmel SE, Localio AR, Metz DC, Farrar JT, Nessel L, et al. Risk of serious upper gastrointestinal toxicity with over-the-counter nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 2005;129(6):1865-74. doi: 10.1053/j.gastro.2005.08.051.

XXXIX. Stosic R, Dunagan F, Palmer H, Fowler T, Adams I. Responsible self-medication: Perceived risks and benefits of over-the-counter analgesic use. Int J Pharm Pract 2011;19(4):236-45. doi: 10.1111/j.2042-7174.2011.00097.x

XL. Shin JY, Park MJ, Lee SH, Choi SH, Kim MH, Choi NK, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ 2015;351(h3517):1-7. doi: 10.1136/bmj.h3517.

XLI. Vandraas KF, Spigset O, Mahic M, Slørdal L. Non-steroidal anti-inflammatory drugs: Use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol 2010;66(8):823-9. doi: 10.1007/S00228-010-0825-2.

XLII. Alqahtani Z, Jamali F. Clinical outcomes of aspirin interaction with other non-steroidal anti-inflammatory drugs: a systematic review. J Pharm Pharm Sci 2018;21(1s):48-73. doi: 10.18433/JPPS29854.

XLIII. Fournier JP, Lapeyre-Mestre M, Sommet A, Dupouy J, Poutrain JC, Montastruc JL. Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study. PLoS One 2012;7(3). doi: 10.1371/JOURNAL.PONE.0034187.

XLIV. Bories M, Bacle A, Gilardi H, Le Corre P. Risk of acute kidney injury by initiation of non-steroidal anti-inflammatory drugs in hospitalised patients treated with diuretics and renin-angiotensin-aldosterone system inhibitors. Eur J Hosp Pharm 2021;29(6):359-61. doi: 10.1136/EJHPHARM-2020-002550.